

# Associations Between At-Risk Alcohol Use, Substance Use, and Smoking with Lipohypertrophy and Lipoatrophy Among Patients Living with HIV

Marisela Noorhasan,<sup>1</sup> Daniel R. Drozd,<sup>1</sup> Carl Grunfeld,<sup>2</sup> Joseph O. Merrill,<sup>1</sup> Greer A. Burkholder,<sup>3</sup> Michael J. Mugavero,<sup>3</sup> James H. Willig,<sup>3</sup> Amanda L. Willig,<sup>3</sup> Karen L. Cropsey,<sup>4</sup> Kenneth H. Mayer,<sup>5</sup> Aaron Blashill,<sup>5</sup> Matthew Mimiaga,<sup>6</sup> Mary E. McCaul,<sup>7</sup> Heidi Hutton,<sup>7</sup> Geetanjali Chander,<sup>8</sup> William C. Mathews,<sup>9</sup> Sonia Napravnik,<sup>10</sup> Joseph J. Eron,<sup>10</sup> Katerina Christopoulos,<sup>2</sup> Rob J. Fredericksen,<sup>1</sup> Robin M. Nance,<sup>1</sup> Joseph Chris Delaney,<sup>11</sup> Paul K. Crane,<sup>1</sup> Michael S. Saag,<sup>3</sup> Mari M. Kitahata,<sup>1</sup> and Heidi M. Crane,<sup>1</sup>  
on behalf of the Centers For AIDS Research Network of Integrated Clinical Systems

## Abstract

To examine associations between lipohypertrophy and lipoatrophy and illicit drug use, smoking, and at-risk alcohol use among a large diverse cohort of persons living with HIV (PLWH) in clinical care. 7,931 PLWH at six sites across the United States completed 21,279 clinical assessments, including lipohypertrophy and lipoatrophy, drug/alcohol use, physical activity level, and smoking. Lipohypertrophy and lipoatrophy were measured using the FRAM body morphology instrument and associations were assessed with generalized estimating equations. Lipohypertrophy (33% mild, 4% moderate-to-severe) and lipoatrophy (20% mild, 3% moderate-to-severe) were common. Older age, male sex, and higher current CD4 count were associated with more severe lipohypertrophy ( $p$  values  $<.001-.03$ ). Prior methamphetamine or marijuana use, and prior and current cocaine use, were associated with more severe lipohypertrophy ( $p$  values  $<.001-.009$ ). Older age, detectable viral load, and low current CD4 cell counts were associated with more severe lipoatrophy ( $p$  values  $<.001-.003$ ). In addition, current smoking and marijuana and opiate use were associated with more severe lipoatrophy ( $p$  values  $<.001-.03$ ). Patients with very low physical activity levels had more severe lipohypertrophy and also more severe lipoatrophy than those with all other activity levels ( $p$  values  $<.001$ ). For example, the lipohypertrophy score of those reporting high levels of physical activity was on average 1.6 points lower than those reporting very low levels of physical activity ( $-1.6$ , 95% CI:  $-1.8$  to  $-1.4$ ,  $p <.001$ ). We found a high prevalence of lipohypertrophy and lipoatrophy among a nationally distributed cohort of PLWH. While low levels of physical activity were associated with both lipohypertrophy and lipoatrophy, associations with substance use and other clinical characteristics differed between lipohypertrophy and lipoatrophy. These results support the conclusion that lipohypertrophy and lipoatrophy are distinct, and highlight differential associations with specific illicit drug use.

**Keywords:** lipoatrophy, lipohypertrophy, substance use, alcohol use, physical activity

<sup>1</sup>Department of Medicine, University of Washington, Seattle, Washington.

<sup>2</sup>Department of Medicine, University of California at San Francisco, San Francisco, California.

Departments of <sup>3</sup>Medicine and <sup>4</sup>Psychiatry, University of Alabama at Birmingham, Birmingham, Alabama.

<sup>5</sup>Department of Medicine, Fenway Institute, Harvard Medical School, Boston, Massachusetts.

<sup>6</sup>Division of Psychiatry, Fenway Institute, Harvard Medical School, Boston, Massachusetts.

Departments of <sup>7</sup>Psychiatry and Behavioral Sciences and <sup>8</sup>Medicine, Johns Hopkins University, Baltimore, Maryland.

<sup>9</sup>Department of Medicine, University of California San Diego, San Diego, California.

<sup>10</sup>Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.

<sup>11</sup>Department of Epidemiology, University of Washington, Seattle, Washington.

## Introduction

OVER THE LAST two decades, there has been a significant decline in HIV-related morbidity and mortality due to antiretroviral therapy (ART).<sup>1,2</sup> This has been accompanied by an increase in the body morphology changes of lipohypertrophy and lipoatrophy.<sup>3</sup> While a decrease in body morphology abnormalities over the next few years due to earlier treatment and the use of less toxic antiretroviral medications has been expected,<sup>4</sup> only a small decrease in lipoatrophy as measured by leg fat percentage has been seen in recent years.<sup>4</sup> While lipohypertrophy and lipoatrophy are often conceptualized as a single disorder called “lipodystrophy,” they are distinct entities with different etiologies.<sup>5–7</sup> Lipohypertrophy is characterized by fat accumulation particularly an increase in visceral fat in the abdomen, enlargement of the dorso-cervical fat pad, and/or fat deposition in breast tissue.<sup>5,8,9</sup> Lipoatrophy is characterized by loss of subcutaneous fat often most pronounced on the face and extremities, with the legs and gluteal region affected more than the upper body.<sup>5,6,8,10</sup>

Metabolic complications of HIV, including lipohypertrophy and lipoatrophy, have been associated with ART, HIV infection itself, and other demographic and lifestyle factors such as age, sex, race/ethnicity, and sedentary lifestyle/physical activity levels.<sup>3,7,8,11–15</sup> Few studies have examined the role of behavioral factors such as substance use, and in particular, prior studies have not evaluated the independent association between lipohypertrophy or lipoatrophy and alcohol, smoking, and illicit drug use, including the role of individual drugs.<sup>5,6,16</sup> Furthermore, behavioral factors such as substance abuse, physical activity, and smoking are often correlated with each other.<sup>17–19</sup> Discerning the unique contributions of at-risk alcohol use, smoking, and other substance use will require considering these factors simultaneously.

We conducted this study to examine the associations between illicit drug use, smoking, and at-risk alcohol use and lipohypertrophy and lipoatrophy among a large, diverse, nationally distributed well-characterized cohort of persons living with HIV (PLWH) in clinical care.

## Methods

### *Study setting*

This observational cohort study was conducted among the Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) cohort. CNICS is a longitudinal observational study of PLWH from eight clinical sites receiving primary care from 1/1/1995 to present.<sup>20</sup>

### *Study subjects*

All PLWH 18 years of age or older who completed one or more clinical assessments of patient-reported outcomes (PROs) as part of a routine clinical visit before 11/2013 were eligible for the study. The PRO clinical assessment was integrated into clinical care between 2006 and 2012 at six participating CNICS sites. The study was approved by Institutional Review Boards at each site.

### *Data sources*

The CNICS data repository captures longitudinal data on the CNICS cohort.<sup>20</sup> The data repository integrates comprehensive clinical data from all outpatient and inpatient en-

counters, including standardized HIV-related information collected at enrollment (initial clinic visit) regarding prior ART history. Demographic, clinical, laboratory, and medication data are obtained from each site’s electronic health record and other institutional data sources.

PLWH used tablet PCs with touch screens to complete the clinical assessment every 4–6 months. The assessment includes a morphology assessment that measures lipohypertrophy and lipoatrophy based on the Study of Fat Redistribution and Metabolic Change instrument (FRAM), which has been validated against objective imaging approaches such as MRI<sup>5,6,21,22</sup> and has key associations with relevant metabolic outcomes such as hypertension, as well as other clinical outcomes such as depression and quality of life.<sup>23,24</sup>

The assessment also includes drug use using a modified Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST),<sup>25,26</sup> alcohol use using the Alcohol Use Disorders Identification Test consumption questions (AUDIT-C),<sup>27,28</sup> cigarette use, and physical activity using the Lipid Research Clinic questionnaire.<sup>29</sup> We used web-based survey software developed specifically for PROs.<sup>30,31</sup> Patients who are medically unstable at the time of a visit, appear intoxicated, or do not speak English or Spanish are not asked to complete the assessment. Given the slow rate of change of body morphology, in 2012, the clinical assessment was programmed with a skip pattern such that it only gives the FRAM body morphology instrument annually even though they can take the assessment every 4–6 months.

### *Measurement of body morphology*

The FRAM body morphology instrument asks PLWH to rate changes in the amount of fat in specific body regions graded on a 7-point scale ranging from –3 to +3 for each region. No change was scored as 0; mild, moderate, and severe increases were scored as +1, +2, and +3; and mild, moderate, and severe decreases were scored as –1, –2, and –3. An overall lipohypertrophy score was calculated totaling all positive responses (indicating increases in size of body regions). An overall lipoatrophy score was calculated totaling all negative responses (indicating decreases in size).

We conducted analyses using three scoring methods for body morphology. We examined lipohypertrophy and lipoatrophy categories (none, 0 points; mild, 1–12 points; and moderate-to-severe, >12 points), and also continuous lipohypertrophy and lipoatrophy scores. We also examined lipohypertrophy and lipoatrophy as binary outcomes (none vs. any).

### *Measurement of substance use*

There are several ways to score the ASSIST to measure substance use.<sup>25,26</sup> We used the ASSIST to operationally define use of four individual drug classes (marijuana, crack/cocaine, methamphetamines/crystal, and illicit opioids/heroin) and categorized use as current (past 3 months), prior, or never.

We calculated AUDIT-C scores for current alcohol use by summing the scores for each item (0–4 points each).<sup>27</sup> We used a score of  $\geq 4$  for men and  $\geq 3$  for women to define at-risk alcohol consumption.<sup>32</sup>

We used responses to the cigarette items to categorize PLWH as current smokers, past or ex-smokers, and non-smokers.

### Measurement of physical activity

This 4-item instrument classifies PLWH into very low active, low active, moderately active, and highly active categories.<sup>29</sup>

### Statistical analyses

We performed bivariate analyses comparing participant characteristics to the overall cohort at the six participating sites using chi-squared tests and *t*-tests. We similarly compared demographic and clinical characteristics of those with completed assessments and those with assessments excluded due to missing body morphology or other information.

We examined associations between body morphology abnormalities, demographic characteristics, clinical characteristics, and behavioral factors. Demographic characteristics included age, race/ethnicity, sex, and HIV transmission risk factor. Clinical characteristics included CD4 count (current and nadir), peak HIV-1 RNA level, current ART use, duration of exposure to stavudine/didanosine, body mass index (BMI), and hepatitis C virus (HCV) status. BMI was measured as a continuous variable and as a categorical variable: underweight <18.5 kg/m<sup>2</sup>, normal 18.5–24.9 kg/m<sup>2</sup>, overweight 25.0–29.9 kg/m<sup>2</sup>, and obese ≥30 kg/m<sup>2</sup>. Duration of stavudine and/or didanosine was included as a key cause of body morphology abnormalities, particularly lipoatrophy.<sup>33</sup> Behavioral factors included current and past illicit drug use, at-risk alcohol use, current and past smoking status, and physical activity levels.

We used generalized estimating equations with an exchangeable correlation structure and robust standard errors to assess differences in body morphology associated with alcohol, cigarette smoking, and other substance use, while accounting for within-subject correlations between repeated measures.<sup>34</sup> Similarly, we used ordinal logistic regression adjusting for repeated measures for categorical lipohypertrophy and lipoatrophy; however, these models failed the assumption of proportional odds. We therefore repeated these analyses using logistic regression with 2 models: one for mild versus none, and the other for moderate-to-severe versus none for categorical lipohypertrophy and lipoatrophy. We conducted separate models for lipohypertrophy and lipoatrophy. We adjusted all analyses for age, race, sex, clinical site, currently receiving ART, duration of prior stavudine/didanosine, current and nadir CD4 cell count, viral load, HCV, at-risk alcohol use, smoking status, physical activity level, and current, past, or no substance use. We adjusted models evaluating lipohypertrophy for lipoatrophy, and adjusted models evaluating lipoatrophy for lipohypertrophy.

We conducted sensitivity analyses by repeating models limited to the subset of individuals known to be naive to ART when they initiated care at a CNICS site to ensure accurate capture of duration of didanosine/stavudine. We also conducted sensitivity analyses focused on belly fat (as an ordinal scale) instead of overall lipohypertrophy. Given the potentially evolving nature of lipohypertrophy and lipoatrophy,<sup>4</sup> we also considered sensitivity analyses with assessment of calendar year. We considered two-tailed *p*-values <.05 to be significant. We used Stata 13 for analyses.

### Results

Clinical assessments were completed 21,279 times by 7,931 PLWH. An additional 2,749 assessments were ex-

cluded due to missing information on body morphology, alcohol, or substance use. The majority of these were due to missing body morphology information as these items are automatically skipped if the body morphology instrument had been completed in the prior 364 days. There were no demographic (age, race, and sex) or clinical differences (CD4 count) for patients from excluded and included assessments. Table 1 describes demographic and clinical characteristics by baseline body morphology at each initial assessment. Mean age was 45 (SD 10), 87% were men, and mean current CD4 count was 523 cells/mm<sup>3</sup> (Table 1). Demographic and clinical characteristics of participants were similar to all individuals receiving care at the participating clinics during the study period (data not shown).

Among all 21,279 assessments, no lipohypertrophy or lipoatrophy was reported during 8,471 clinical assessments (40%), mild lipohypertrophy was reported during 7,123 assessments (33%), mild lipoatrophy was reported during 4,301 (20%) assessments, moderate-to-severe lipohypertrophy was reported in 803 (4%) assessments, and moderate-to-severe lipoatrophy was reported in 582 (3%) assessments. While it is theoretically possible for an individual to have both moderate-to-severe lipohypertrophy and moderate-to-severe lipoatrophy in different regions, this was only reported during two assessments. There were 157 assessments with moderate-to-severe lipohypertrophy and mild lipoatrophy (<1%), and 140 where individuals reported moderate-to-severe lipoatrophy and mild lipohypertrophy (<1%). There were 2,604 assessments where individuals reported both mild lipohypertrophy and mild lipoatrophy (12%). Individuals with both lipohypertrophy and lipoatrophy were categorized according to whichever was more severe; in the case of a tie (411 assessments, 1.9%), people were categorized as having lipoatrophy.

Bivariate analyses at baseline, female sex, older age, higher BMI, very low physical activity levels, and currently receiving ART (Table 1) were associated with lipohypertrophy. In contrast, older age, lower current and nadir CD4 cell counts, lower BMI, and very low physical activity levels were associated with lipoatrophy in bivariate analyses (Table 1).

When we examined substance use, rates of baseline body morphology category differed among PLWH who reported never, prior, or current use of opiates, cocaine/crack, methamphetamines, and marijuana (*p* values <.001,  $\chi^2$ ). A consistent pattern of body morphology was seen for only some drugs (Table 2). Smoking, but not current at-risk alcohol use, was associated with lipoatrophy and, in particular, current smoking was associated with moderate-to-severe lipoatrophy.

### Multivariate analyses

Older age, female sex, and higher current CD4 count were all associated with more severe lipohypertrophy using continuous lipohypertrophy scores in adjusted analyses (*p* values <.001–.03). In contrast, a higher CD4 cell count nadir and more than very low levels of physical activity were associated with less severe lipohypertrophy (*p* values .001–.02) (Fig. 1). For example, the lipohypertrophy score of those reporting high levels of physical activity was on average 1.6 points lower than those reporting very low levels of physical activity (−1.6, 95% CI: −1.8 to −1.4, *p* <.001).

TABLE 1. DEMOGRAPHIC AND CLINICAL CHARACTERISTICS OF PATIENTS AT INITIAL ASSESSMENT CATEGORIZED BY BODY MORPHOLOGY (N=7,931)

Characteristic	Lipohypertrophy						Lipoatrophy					
	Neither lipoatrophy nor lipohypertrophy		Mild		Moderate-to-severe		p value*	Mild		Moderate-to-severe		p value**
	N=3,156		N=2,607		N=260			N=1,664		N=244		
N	%	N	%	N	%	N	%	N	%	N	%	
Sex												
Male	2760	87%	2240	86%	177	68%		153	92%	207	85%	
Female	396	13%	367	14%	83	32%	<.001	134	8%	37	15%	<.001
Race												
White	1538	49%	1486	57%	129	50%		942	57%	135	55%	
Black	927	29%	602	23%	70	27%		353	21%	54	22%	
Hispanic	531	17%	397	15%	52	20%		294	18%	45	18%	
Other/Unknown	160	5%	122	5%	9	4%	<.001	75	5%	10	4%	<.001
Age (years)												
<30	447	14%	224	9%	19	7%		178	11%	18	7%	
30–39	800	25%	543	21%	44	17%		342	21%	31	13%	
40–49	1144	36%	1092	42%	120	46%		671	41%	97	40%	
≥50	765	24%	748	30%	77	30%	<.001	473	28%	98	40%	<.001
HIV transmission risk factor												
MSM	1994	63%	1652	63%	135	52%		1114	67%	128	52%	
IDU	308	10%	351	13%	37	14%		225	14%	34	14%	
MSM & IDU	69	2%	61	2%	5	2%		42	3%	5	2%	
Heterosexual	705	22%	471	18%	78	30%		236	14%	61	25%	
Other/Unknown	80	3%	72	3%	5	2%	<.001	47	3%	16	7%	<.001
CD4 <sup>+</sup> cell count nadir (cells/mm <sup>3</sup> )												
0–200	1456	46%	1254	48%	142	55%		790	47%	153	63%	
201–350	897	28%	712	27%	50	19%		421	25%	49	20%	
>350	803	25%	641	25%	68	26%	.02	453	27%	42	17%	<.001
CD4 <sup>+</sup> cell count current (cells/mm <sup>3</sup> )												
0–200	427	14%	325	12%	34	13%		271	16%	84	34%	
201–350	584	19%	440	17%	46	18%		294	18%	41	17%	
>350	2145	68%	1842	71%	180	69%	.3	1099	66%	119	49%	<.001
Hepatitis C virus												
No	2699	86%	2078	80%	211	81%		1328	80%	180	74%	
Yes	457	14%	529	20%	49	19%	<.001	336	20%	64	26%	<.001
Physical Activity Level												
Very low	575	18%	778	30%	111	43%		466	28%	117	48%	
Low	1483	47%	1154	44%	111	43%		654	39%	79	32%	
Moderate	613	19%	435	17%	29	11%		343	21%	30	12%	
High	485	15%	240	9%	9	3%	<.001	201	12%	18	7%	<.001
BMI (N=7,830)												
<18.5	80	3%	13	<1%	8	3%		53	3%	28	11%	
18.5–24.9	1351	43%	684	27%	33	13%		810	49%	151	62%	
25–29.9	1285	41%	1278	50%	81	32%		624	38%	55	23%	
≥30	440	14%	563	22%	134	52%	<.001	149	9%	10	4%	<.001
Currently receiving ART												
Yes	2339	74%	2144	82%	223	86%		1341	81%	184	75%	
No	817	26%	463	18%	37	14%	<.001	323	19%	60	25%	<.001

Individuals with both lipoatrophy and lipohypertrophy are categorized by the more severe body morphology.

\*Chi<sup>2</sup> of no body morphology versus mild lipohypertrophy versus moderate-to-severe lipohypertrophy.

\*\*Chi<sup>2</sup> of no body morphology versus mild lipoatrophy versus moderate-to-severe lipoatrophy.

MSM, men who have sex with men; IDU, injection drug user; BMI body mass index.

In models adjusting for demographic and clinical factors, prior methamphetamine use, prior and current cocaine use, and prior marijuana use were all associated with more severe lipohypertrophy using the continuous scale ( $p$  values <.001–.009), while current cigarette smoking was associated with less severe lipohypertrophy ( $p$  value .05) (Fig. 1). There was no association with opiate or at-risk alcohol use.

Many of the same factors were associated with binary lipohypertrophy (any vs. none, Table 3, model 1) as an outcome. In addition, black race was significantly associated with being less likely to have lipohypertrophy compared with white race, and current ART use was associated with lipohypertrophy ( $p$  <.001–0.02). For example, a higher current CD4 cell count was associated with lipohypertrophy (CD4

TABLE 2. SUBSTANCE USE AT INITIAL ASSESSMENT CATEGORIZED BY BODY MORPHOLOGY (N=7,931)

Characteristic	Neither lipoatrophy nor lipohypertrophy N = 3,156		Lipohypertrophy				p-value*	Lipoatrophy				p-value**
			Mild		Moderate-to-severe			Mild		Moderate-to-severe		
			N	%	N	%		N	%	N	%	
Methamphetamine use												
None	2153	68%	1420	55%	159	61%		869	52%	147	60%	
Prior	695	22%	886	34%	87	33%		523	31%	68	28%	
Current	309	10%	301	12%	14	5%	<.001	272	16%	29	12%	<.001
Cocaine use												
None	1799	57%	1161	45%	138	53%		728	44%	118	48%	
Prior	1143	36%	1226	47%	106	41%		780	47%	102	42%	
Current	214	7%	220	8%	16	6%	<.001	156	9%	24	10%	<.001
Opiate use												
None	2850	90%	2186	84%	218	84%		1377	83%	203	83%	
Prior	244	8%	352	14%	35	13%		227	14%	30	12%	
Current	62	2%	69	3%	7	3%	<.001	60	4%	11	5%	<.001
Marijuana use												
None	1296	41%	754	29%	103	40%		446	27%	88	36%	
Prior	1019	32%	1049	40%	96	37%		553	33%	74	30%	
Current	841	27%	804	31%	61	23%	<.001	665	39%	82	34%	<.001
Alcohol use												
Not at risk	2630	83%	2152	83%	231	89%		1370	82%	211	86%	
At-risk	526	17%	455	17%	29	11%	.03	294	18%	33	14%	.2
Cigarette smoking												
None	1301	41%	895	34%	94	36%		494	30%	64	26%	
Prior	710	23%	753	29%	74	28%		449	27%	59	24%	
Current	1145	36%	959	37%	92	36%	<.001	721	43%	121	50%	<.001

\*Chi<sup>2</sup> of no body morphology versus mild lipohypertrophy versus moderate-to-severe lipohypertrophy.

\*\*Chi<sup>2</sup> of no body morphology versus mild lipoatrophy versus moderate-to-severe lipoatrophy.

Patients with both lipoatrophy and lipohypertrophy are categorized by the more severe body morphology.

cell count 201–350, OR 1.2; 95% CI 1.1–1.4,  $p = .005$ ; CD4 cell count >350 OR 1.4; 95% CI 1.2–1.6,  $p < .001$  compared to CD4 count  $\leq 200$ ) as was prior marijuana use compared with no use (OR 1.3, 95% CI: 1.2–1.4,  $p < .001$ ). The association with current cocaine use was no longer significant ( $p = .1$ ). Findings were similar in analyses that used a categorical lipohypertrophy outcome (none, mild, and moderate–severe lipohypertrophy Table 3, model 2). Findings were also similar in a model focused specifically on belly fat as the outcome (data not shown) with a similar pattern of findings as those seen with the categorical lipohypertrophy outcome shown in Table 3, model 2, except that the association with current cocaine use did not reach statistical significance.

With regard to lipoatrophy, older age, detectable viral load, and low current CD4 cell counts were associated with more severe lipoatrophy using continuous lipoatrophy scores in adjusted analyses, while African American or black race was associated with less severe lipoatrophy ( $p$  values <.001–.008) (Fig. 1). For example, those with a current CD4 cell count of >350 cells/mm<sup>3</sup> had an average lipoatrophy score 1 point lower than those with a CD4 count <200 cells/mm<sup>3</sup> (–1.0, 95% CI: –1.2 to –0.7,  $p < .001$ ). Compared with PLWH with very low physical activity levels, all other activity levels were associated with less severe lipoatrophy ( $p$  values <.001).

In a model adjusting for demographic and clinical factors, current cigarette smoking, marijuana use, and opiate use were


all associated with more severe lipoatrophy ( $p$  values <.001–.03). In sharp contrast, there was a protective finding for at-risk alcohol use ( $p = .001$ ) (Fig. 1).

The same factors were associated with lipoatrophy as a binary outcome (any vs. none), but in addition, male sex (OR 1.2; 95% CI 1.0–1.3,  $p = .03$ ), current ART (OR 1.3; 95% CI 1.1–1.5,  $p < .001$ ), and methamphetamine use (OR 1.3; 1.1–1.5,  $p < .001$ ) were also significantly associated with lipoatrophy (Table 4, model 1). Findings were also similar in adjusted analyses that used a categorical outcome for lipoatrophy (none, mild, and moderate–severe lipoatrophy, Table 4, model 2).

We conducted sensitivity analyses limited to the 10,442 assessments completed by those known to be ART naive when they enrolled in CNICS. Findings from these sensitivity analyses were similar to those from the entire study cohort (data not shown). Findings from sensitivity analyses that also included calendar year were similar to those main models (data not shown).

## Discussion

In this study of 7,931 PLWH from six clinics from across the United States, we found a high prevalence of body morphology abnormalities: 60% had at least some degree of lipoatrophy or lipohypertrophy. Most abnormalities were mild, with only a small percentage reporting moderate-to-severe



**FIG. 1.** Mean differences in continuous lipohypertrophy (a) and lipoatrophy (b) scores by demographic, clinical, and behavioral factors in adjusted analyses.

lipohypertrophy (4%) or moderate-to-severe lipoatrophy (3%). Behavioral factors differed in their associations with lipohypertrophy and lipoatrophy, highlighting the importance of considering these two distinct outcomes separately rather than combining them. Prior methamphetamine, cocaine, and marijuana use and current cocaine use were associated with more severe lipohypertrophy, although the impact of each of these individual factors was small. Current opiate and marijuana use, and current and past cigarette smoking were all associated with more severe lipoatrophy in adjusted analyses. Higher physical activity levels were associated with less severe lipohypertrophy and less severe lipoatrophy.

#### Alcohol use

Alcohol use may increase the risk of lipodystrophy based on a link between alcoholism and the development of abnormal fat growth with mitochondrial replication deficits.<sup>35</sup> This prior study did not find an association between alcohol use and lipodystrophy, although there was a possible association between alcohol use and lipohypertrophy.<sup>35</sup> Other studies have also not found associations between alcohol use and lipodystrophy,<sup>5,6,15,36</sup> although few examined the distinct outcomes of lipohypertrophy and lipoatrophy.<sup>5,6</sup> The best information to date is from FRAM, which did not find associations between alcohol use and lipohypertrophy mea-

sured by visceral adipose tissue (VAT) or lipoatrophy measured by leg subcutaneous adipose tissue (SAT).<sup>5,6</sup> While FRAM had a smaller sample size than this study, a FRAM strength was the rigorous approach to body morphology measurement.<sup>5,6</sup>

We found an association between current at-risk alcohol use and a slight decrease in risk of lipoatrophy, and did not find an association between at-risk alcohol use and lipohypertrophy. While the association between alcohol use and lower risk for lipoatrophy is intriguing, this study does not allow conclusions to be drawn regarding the direction of the association. It may be that more severe lipoatrophy and associated factors, including longer duration of HIV infection, may be leading to less alcohol use rather than the reverse. Understanding the potential impacts of alcohol use on body morphology and other outcomes is important given the high prevalence of at-risk alcohol use among PLWH.<sup>30,37,38</sup>

#### Substance use

General population studies have provided conflicting findings on the associations between body morphology, BMI, or body weight status and specific substances with different findings for past versus current use as well as men versus women.<sup>39-41</sup> Despite this, some substances, such as alcohol, nicotine, and marijuana potentially impact appetite.<sup>42-44</sup>

TABLE 3. ASSOCIATION BETWEEN DEMOGRAPHIC, CLINICAL, AND BEHAVIORAL FACTORS AND LIPOHYPERTROPHY IN ADJUSTED ANALYSES

	<i>Model 1</i>	<i>Model 2a</i>	<i>Model 2b</i>
	<i>Lipohypertrophy binary (none vs. any) OR, 95% CI, p-value</i>	<i>Lipohypertrophy categorical (none vs. mild) OR, 95% CI, p-value</i>	<i>Lipohypertrophy categorical (none vs. moderate-severe) OR, 95% CI, p-value</i>
Sex			
Female	Ref	Ref	Ref
Male	0.7; 0.6–0.8, <b>&lt;.001</b>	0.7; 0.7–0.8, <b>&lt;.001</b>	0.3; 0.3–0.4, <b>&lt;.001</b>
Race			
White	Ref	Ref	Ref
Black	0.9; 0.8–1.0, <b>.02</b>	0.9; 0.8–1.0, <b>.004</b>	1.2; 0.9–1.5, .3
Hispanic	1.0; 0.9–1.1, .5	0.9; 0.8–1.0, .3	1.3; 1.0–1.7, .07
Other	0.8; 0.6–0.9, <b>.01</b>	0.8; 0.6–1.0, <b>.02</b>	0.9; 0.4–1.7, .7
Age (per year)	1.01; 1.00–1.01, <b>&lt;.001</b>	1.01; 1.00–1.01, <b>&lt;.001</b>	1.01; 1.00–1.02, .1
CD4 <sup>+</sup> cell count nadir (cells/mm <sup>3</sup> )			
0–200	Ref	Ref	Ref
201–350	0.8; 0.8–0.9, <b>.006</b>	0.9; 0.8–1.0, <b>.004</b>	0.5; 0.4–0.7, <b>&lt;.001</b>
351 or greater	0.9; 0.8–1.0, <b>.005</b>	0.9; 0.8–1.0, <b>.01</b>	0.8; 0.6–1.0, .07
Current CD4 <sup>+</sup> cell count (cells/mm <sup>3</sup> )			
0–200	Ref	Ref	Ref
201–350	1.2; 1.1–1.4, <b>.005</b>	1.2; 1.0–1.3, <b>.03</b>	1.3; 0.9–1.8, .1
351 or greater	1.4; 1.2–1.6, <b>&lt;.001</b>	1.3; 1.2–1.5, <b>&lt;.001</b>	1.5; 1.1–2.1, <b>.01</b>
Current viral load			
Detectable	Ref	Ref	Ref
Undetectable	1.2; 1.1–1.3, <b>&lt;.001</b>	1.2; 1.0–1.3, <b>.005</b>	1.2; 1.0–1.6, .1
Current antiretroviral medications			
No	Ref	Ref	Ref
Yes	1.2; 1.1–1.4, <b>.001</b>	1.2; 1.0–1.3, <b>.005</b>	1.5; 1.1–2.0, <b>.01</b>
D4T or DDI use (per year)	1.03; 1.01–1.05, <b>.003</b>	1.03; 1.01–1.05, <b>&lt;.001</b>	1.06; 1.01–1.11, <b>.02</b>
Methamphetamine use			
None	Ref	Ref	Ref
Prior	1.2; 1.1–1.4, <b>&lt;.001</b>	1.2; 1.1–1.4, <b>&lt;.001</b>	1.0; 0.8–1.4, .8
Current	1.1; 0.9–1.2, .3	1.1; 0.9–1.2, .3	0.6; 0.4–1.0, <b>.04</b>
Cocaine use			
None	Ref	Ref	Ref
Prior	1.2; 1.1–1.3, <b>&lt;.001</b>	1.2; 1.1–1.3, <b>.002</b>	1.7; 1.3–2.3, <b>&lt;.001</b>
Current	1.1; 1.0–1.3, .1	1.1; 1.0–1.3, .1	1.6; 1.0–2.6, <b>.03</b>
Opiate use			
None	Ref	Ref	Ref
Prior	1.1; 0.9–1.2, .4	1.1; 0.9–1.2, .4	1.1; 0.8–1.5, .5
Current	1.0; 0.8–1.3, .8	1.0; 0.8–1.3, .8	1.2; 0.6–2.4, .7
Marijuana use			
None	Ref	Ref	Ref
Prior	1.3; 1.2–1.4, <b>&lt;.001</b>	1.3; 1.2–1.4, <b>&lt;.001</b>	1.2; 0.9–1.5, .2
Current	1.1; 1.0–1.2, .09	1.1; 1.0–1.2, <b>.03</b>	0.8; 0.6–1.1, .2
Cigarette smoking			
Never	Ref	Ref	Ref
Prior	1.1; 1.0–1.3, .09	1.2; 1.0–1.3, <b>.005</b>	1.0; 0.8–1.3, .8
Current	0.9; 0.8–1.0, <b>.05</b>	0.9; 0.8–1.0, .08	0.8; 0.6–1.1, .2
Alcohol use			
Not at-risk	Ref	Ref	Ref
At-risk	1.1; 1.0–1.2, .2	1.1; 1.0–1.2, .3	0.7; 0.5–0.9, <b>.02</b>
Physical activity level			
Very low	Ref	Ref	Ref
Low	0.6; 0.6–0.7, <b>&lt;.001</b>	0.7; 0.6–0.7, <b>&lt;.001</b>	0.4; 0.3–0.4, <b>&lt;.001</b>
Moderate	0.6; 0.6–0.7, <b>&lt;.001</b>	0.6; 0.6–0.7, <b>&lt;.001</b>	0.3; 0.2–0.4, <b>&lt;.001</b>
High	0.4; 0.4–0.5, <b>&lt;.001</b>	0.4; 0.4–0.5, <b>&lt;.001</b>	0.1; 0.1–0.2, <b>&lt;.001</b>

Also adjusted for site, HCV status, and lipoatrophy.  
All associations presented are adjusted Odds Ratios.  
*p* values <0.05 are *bolded*.

TABLE 4. ASSOCIATION BETWEEN DEMOGRAPHIC, CLINICAL, AND BEHAVIORAL FACTORS AND LIPOATROPHY IN ADJUSTED ANALYSES

	<i>Model 1</i>	<i>Model 2a</i>	<i>Model 2b</i>
	<i>Lipoatrophy binary (none vs. any) OR, 95% CI, p-value</i>	<i>Lipoatrophy categorical (none vs. mild) OR, 95% CI, p-value</i>	<i>Lipoatrophy categorical (none vs. moderate-severe) OR, 95% CI, p-value</i>
Sex			
Female	Ref	Ref	Ref
Male	1.2; 1.0–1.3, <b>.03</b>	1.2; 1.0–1.3, <b>.04</b>	0.8 0.6–1.2, .3
Race			
White	Ref	Ref	Ref
Black	0.8; 0.7–0.9, <b>&lt;.001</b>	0.8; 0.7–0.9, <b>&lt;.001</b>	0.7; 0.6–1.0, <b>.04</b>
Hispanic	1.0; 0.9–1.2, .4	1.0; 0.9–1.2, .5	1.2; 0.9–1.5, .3
Other	0.7 0.6–0.9, <b>.008</b>	0.7; 0.6–0.9, <b>.008</b>	0.9; 0.5–1.6, .8
Age (per year)	1.02; 1.02–1.03, <b>&lt;.001</b>	1.02; 1.02–1.02, <b>&lt;.001</b>	1.04; 1.03–1.05, <b>&lt;.001</b>
CD4 <sup>+</sup> cell count nadir (cells/mm <sup>3</sup> )			
0–200	Ref	Ref	Ref
201–350	1.0; 0.9–1.1, .7	1.0; 0.9–1.1, .6	0.9; 0.7–1.2, .5
351 or greater	1.1; 1.0–1.2, .1	1.1; 1.0–1.3, .06	0.9; 1.6–1.2, .4
Current CD4 <sup>+</sup> cell count (cells/mm <sup>3</sup> )			
0–200	Ref	Ref	Ref
201–350	0.8; 0.7–0.9, <b>.001</b>	0.9; 0.8–1.0, <b>.03</b>	0.5; 0.4–0.7, <b>&lt;.001</b>
351 or greater	0.8; 0.7–0.9, <b>&lt;.001</b>	0.9; 0.8–1.0, <b>.03</b>	0.4; 0.3–0.6, <b>&lt;.001</b>
Current viral load			
Detectable	Ref	Ref	Ref
Undetectable	0.8; 0.7–0.9, <b>&lt;.001</b>	0.8; 0.7–0.9, <b>.001</b>	0.7; 0.5–0.9, <b>.005</b>
Current antiretroviral medications			
No	Ref	Ref	Ref
Yes	1.3; 1.1–1.5, <b>&lt;.001</b>	1.3; 1.2–1.5, <b>&lt;.001</b>	1.1; 0.8–1.5, .5
D4T or DDI use (per year)	1.1; 1.0–1.1, <b>&lt;.001</b>	1.1; 1.0–1.1, <b>&lt;.001</b>	1.1; 1.0–1.1, <b>&lt;.001</b>
Methamphetamine use			
None	Ref	Ref	Ref
Prior	1.1; 0.9–1.2, .4	1.1; 0.9–1.2, .4	1.0; 0.7–1.3, 1.0
Current	1.3; 1.1–1.5, <b>&lt;.001</b>	1.4; 1.2–1.6, <b>&lt;.001</b>	0.8; 0.5–1.1, .2
Cocaine use			
None	Ref	Ref	Ref
Prior	1.0; 0.9–1.1, .9	1.0; 0.9–1.1, .8	1.0; 0.7–1.3, 1.0
Current	1.1; 0.9–1.2, .6	1.0; 0.9–1.2, .6	1.4; 1.0–2.2, .08
Opiate use			
None	Ref	Ref	Ref
Prior	1.1; 1.0–1.2, .2	1.1; 0.9–1.2, .2	1.3; 1.0–1.8, .09
Current	1.3; 1.0–1.7, <b>.02</b>	1.2; 1.0–1.7, <b>.04</b>	2.0; 1.2–3.3, <b>.009</b>
Marijuana use			
None	Ref	Ref	Ref
Prior	1.1; 1.0–1.3, <b>.03</b>	1.1; 1.0–1.3, <b>.01</b>	1.0; 0.7–1.3, .8
Current	1.6; 1.4–1.8, <b>&lt;.001</b>	1.6; 1.4–1.8, <b>&lt;.001</b>	1.6; 1.2–2.1, <b>.001</b>
Cigarette smoking			
Never	Ref	Ref	Ref
Prior	1.2; 1.0–1.3, <b>.01</b>	1.1; 1.0–1.3, <b>.04</b>	1.5; 1.1–2.0, <b>.008</b>
Current	1.2; 1.1–1.4, <b>&lt;.001</b>	1.2; 1.1–1.3, <b>&lt;.001</b>	1.6; 1.2–2.0, <b>.001</b>
Alcohol use			
Not at risk	Ref	Ref	Ref
At-risk	0.9; 0.8–0.9, <b>.002</b>	0.8; 0.7–0.9, <b>&lt;.001</b>	0.7; 0.5–1.0, <b>.05</b>
Physical activity level			
Very low	Ref	Ref	Ref
Low	0.7; 0.7–0.8, <b>&lt;.001</b>	0.8; 0.7–0.8, <b>&lt;.001</b>	0.3; 0.3–0.4, <b>&lt;.001</b>
Moderate	0.9; 0.8–1.0, <b>.02</b>	0.9; 0.8–1.0, .2	0.4; 0.3–0.5, <b>&lt;.001</b>
High	0.8; 0.7–1.0, <b>.01</b>	0.9; 0.8–1.1, .2	0.3; 0.2–0.4, <b>&lt;.001</b>

Also adjusted for site, HCV status, and lipohypertrophy.  
 All associations presented are adjusted Odds Ratios.  
*p* values <0.05 are *bolded*.



In HIV-infected populations, one prior study suggested substance use was not a predictor of regional fat distribution;<sup>36</sup> however, this study was limited to Hispanic individuals and only examined current substance use, not past use. The authors did not distinguish between current and past use and did not evaluate individual drugs. Similarly, the FRAM study did not find associations between substance use and SAT or VAT.<sup>5,6</sup>

We found that prior methamphetamine and cocaine use were associated with lipohypertrophy, while current use of drugs such as marijuana and illicit opiates/heroin was associated with lipoatrophy. While associations between body morphology and individual drugs were small, it is notable that these associations are in the setting of adjusting for other illicit drugs as well as alcohol, smoking, and physical activity levels. We found key differences between associations of individual drugs with either lipohypertrophy or lipoatrophy. Our results reinforce the importance of examining the impact of drug use separately for each outcome.

### *Smoking*

There are limited studies examining associations between smoking and lipohypertrophy and lipoatrophy. One small study did not find an association between smoking and lipodystrophy.<sup>15</sup> The FRAM study found an association between being a current smoker and less lipohypertrophy as measured by VAT, but did not find an association between being a current smoker and lipoatrophy as measured by SAT.<sup>5,6</sup> Another small study among Hispanic patients<sup>36</sup> found current smokers had less truncal fat consistent with our findings that current smoking was associated with less severe lipohypertrophy. The prior study of Hispanic patients also found that among males, current smokers had more appendicular fat.<sup>36</sup> In contrast, we found that in analyses that also took into account substance and alcohol use, the current and past smoking were both associated with more severe lipoatrophy.

### *Physical activity*

Prior studies often focused on lipodystrophy rather than lipohypertrophy and lipoatrophy. They found associations between physical activity level and lipodystrophy,<sup>15,45</sup> but were small studies unable to look at the simultaneous impact of physical activity and other behavioral factors.<sup>45</sup> An early trial of patients on indinavir, lamivudine, and either stavudine or zidovudine found that the absence of physical activity was associated with developing lipoatrophy, but not lipohypertrophy.<sup>46</sup> Other studies found a relationship between physical activity and lack of central fat accumulation<sup>47</sup> and moderate physical activity and waist circumference.<sup>48</sup> The FRAM study found an association between physical activity quartile and less SAT and VAT among men, and a suggestion of an association between physical activity and SAT, but not VAT among women.<sup>5,6</sup>

Our findings demonstrated associations between higher physical activity levels and both decreased lipohypertrophy and lipoatrophy across the spectrum of physical activity levels even when adjusting for other key behavioral factors that are often associated with physical activity levels. These findings suggest a possible protective association for higher levels of physical activity.

### *Measurement or scoring of lipohypertrophy and lipoatrophy*

Self-reported body morphology abnormalities have been scored in several ways, including as binary, categorical, and continuous outcomes.<sup>49–53</sup> Few comparisons have been made between approaches. Categorizing or dichotomizing outcomes can be advantageous for improving interpretability and ease of describing results. However, loss of information and loss of power have been described for dichotomizing or categorizing continuous data.<sup>54</sup>

We found differences using three scoring approaches, for example, current cocaine use was associated with lipohypertrophy when using the continuous and categorical approaches, but not binary, and the association between current ART use and lipohypertrophy was significant only with categorical and binary scoring, although the size of the association was also similar and suggestive to using continuous scoring. While differences existed, the pattern of findings was consistent for most associations across the three approaches. Furthermore, given the small differences in associations between scoring approaches, but the large differences in the associations between lipohypertrophy versus lipoatrophy, these findings suggest that differences in scoring approaches for lipohypertrophy and lipoatrophy have an impact, but that it is much smaller than the misclassification, loss of information, and potential erroneous conclusions that can be made by combining lipohypertrophy and lipoatrophy into one outcome.

### *Strengths*

A study strength was the assessment of individual illicit drug use, including current and past use in adjusted models that simultaneously consider other drugs, alcohol use, cigarette use, and physical activity levels. Drug use is often associated with other harmful behaviors such as smoking and alcohol use. The large sample size and comprehensive clinical data available, including information from the CNICS clinical assessment, facilitated examining the associations of these behaviors simultaneously. Use of the FRAM body morphology measure was an additional strength allowing us to examine both independent effects of lipohypertrophy and lipoatrophy as well as differences by the severity of body morphology abnormality. An advantage of FRAM assessments over DEXA scans or single-cut CT scans is that FRAM allows facial lipoatrophy changes to be included.

### *Limitations*

A limitation of this study is the relevance of body morphology abnormalities, particularly lipoatrophy in the current ART era. However, while key risk factors such as stavudine are rarely, if ever, used in care currently, many PLWH have now been alive and in care for many years. The percentage reporting lipoatrophy (mild or moderate-to-severe) in care in CNICS in 2015 (22%) was similar to the percentage in the study overall as shown in the results section (23%), suggesting that understanding these associations and mechanisms is still relevant in the current treatment era. Our study design precluded us from drawing conclusions regarding causality. We suspect that lower physical activity levels lead to increased risk of body morphology abnormalities; however, longitudinal studies are needed to elucidate these

relationships. Associations with lipohypertrophy can be complicated by misclassification and overlap with obesity. We do not address whether associations are due to direct effects of illicit drugs versus indirect effects, such as by changes in appetite. We focused on current alcohol use; all nondrinkers were a single group, including people who were never at-risk alcohol drinkers and people with prior at-risk alcohol use who became nondrinkers.<sup>55,56</sup> Additional studies are needed that parse these nuances before the potential impact of alcohol use on body morphology among PLWH can be well understood. An additional limitation is the potential for Type 1 errors when evaluating multiple covariates with two outcomes each of which has three parameterizations. Patterns of association that are similar across the three parameterizations provide some reassurance that those associations are less likely due to Type 1 errors. Finally, while the self-reported morphology assessment included in this study allowed inclusion of facial changes, MRI-based depot measures provide slightly different results.<sup>5,6</sup> Self-reported morphology results are closer to the perceived clinical syndrome. However, the differences between these results may shed light on how drug use affects perception as well as adipose tissue.

## Conclusions

We found a high prevalence of lipohypertrophy and lipoatrophy among this nationally distributed clinical cohort of PLWH, although most of these abnormalities were mild. Behavioral factors differed in their associations with lipohypertrophy and lipoatrophy. Prior methamphetamine, cocaine, and marijuana use and current cocaine use were associated with more severe lipohypertrophy. Current opiate and marijuana use, and current and past smoking were all associated with more severe lipoatrophy. While low levels of physical activity are associated with both lipohypertrophy and lipoatrophy, associations with substance use and other clinical characteristics differed between lipohypertrophy and lipoatrophy. These results support the conclusion that lipohypertrophy and lipoatrophy are distinct and should be examined separately rather than combined. These results also highlight the importance of examining the impact of drug use by an individual class of drug. These results may prove useful in counseling patients who wish to avoid body morphology changes and further our understanding of associations with these conditions and their possible mechanisms.

## Acknowledgments

We thank the patients and providers throughout the CNICS network.

We thank the participating clinical sites within CNICS: the University of Washington (UW) Harborview Medical Center HIV Clinic, the University of Alabama at Birmingham (UAB) 1917 HIV/AIDS Clinic, Fenway Community Health Center of Harvard University (Fenway), University of California San Diego HIV Clinic (UCSD), University of North Carolina at Chapel Hill (UNC), and University of California San Francisco HIV Clinic (UCSF).

This work was supported by the National Institutes of Alcohol Abuse and Alcoholism (NIAAA) at the National Institutes of Health [U24AA020801, U01AA020793 and U01AA020802]. Additional support came from the National

Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health [CNICS R24 AI067039, UW CFAR NIAID Grant P30 AI027757; UNC CFAR grant P30 AI50410, and UAB CFAR grant P30 AI027767].

Findings were presented, in part, at the 22nd Conference on Retroviruses and Opportunistic Infections, Seattle, 2015.

## Author Disclosure Statement

No competing financial interests exist.

## References

1. Palella FJ, Jr., Delaney KM, Moorman AC, *et al.*: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 1998;338: 853–860.
2. Hogg RS, Heath KV, Yip B, *et al.*: Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. *JAMA* 1998;279:450–454.
3. Tsiodras S, Mantzoros C, Hammer S, Samore M: Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. *Arch Intern Med* 2000; 160:2050–2056.
4. Guaraldi G, Stentarelli C, Zona S, *et al.*: The natural history of HIV-associated lipodystrophy in the changing scenario of HIV infection. *HIV Med* 2014;15:587–594.
5. Fat Redistribution and Metabolic Change in HIV Infection (FRAM) Investigators: Fat distribution in women with HIV infection. *J Acquir Immune Defic Syndr* 2006;42:562–571.
6. Bacchetti P, Gripshover B, Grunfeld C, *et al.*: Fat distribution in men with HIV infection. *J Acquir Immune Defic Syndr* 2005;40:121–131.
7. de Waal R, Cohen K, Maartens G: Systematic review of antiretroviral-associated lipodystrophy: Lipoatrophy, but not central fat gain, is an antiretroviral adverse drug reaction. *PLoS One* 2013;8:e63623.
8. Koutkia P, Grinspoon S: HIV-associated lipodystrophy: Pathogenesis, prognosis, treatment, and controversies. *Annu Rev Med* 2004;55:303–317.
9. Handelsman Y, Oral EA, Bloomgarden ZT, *et al.*: The clinical approach to the detection of lipodystrophy - an AACE consensus statement. *Endocr Pract* 2013;19:107–116.
10. Currier J, Scherzer R, Bacchetti P, *et al.*: Regional adipose tissue and lipid and lipoprotein levels in HIV-infected women. *J Acquir Immune Defic Syndr* 2008;48:35–43.
11. Mallal SA, John M, Moore CB, James IR, McKinnon EJ: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. *AIDS* 2000;14:1309–1316.
12. Chen D, Misra A, Garg A: Clinical review 153: Lipodystrophy in human immunodeficiency virus-infected patients. *J Clin Endocrinol Metab* 2002;87:4845–4856.
13. Carr A, Samaras K, Chisholm DJ, Cooper DA: Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. *Lancet* 1998;351:1881–1883.
14. Anjos EM, Pfrimer K, Machado AA, Cunha SF, Salomao RG, Monteiro JP: Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up. *Clinics* 2011;66:407–410.
15. Justina LB, Luiz MC, Maurici R, Schuelter-Trevisol F: Prevalence and factors associated with lipodystrophy in AIDS patients. *Rev Soc Bras Med Trop* 2014;47:30–37.

16. Armellini F, Zamboni M, Frigo L, *et al.*: Alcohol consumption, smoking habits and body fat distribution in Italian men and women aged 20–60 years. *Eur J Clin Nutr* 1993;47:52–60.
17. Degenhardt L, Hall W: The relationship between tobacco use, substance-use disorders and mental health: Results from the National Survey of Mental Health and Well-being. *Nicotine Tob Res* 2001;3:225–234.
18. Gollenberg A, Pekow P, Markenson G, Tucker KL, Chasan-Taber L: Dietary behaviors, physical activity, and cigarette smoking among pregnant Puerto Rican women. *Am J Clin Nutr* 2008;87:1844–1851.
19. Paavola M, Vartiainen E, Haukkala A: Smoking, alcohol use, and physical activity: A 13-year longitudinal study ranging from adolescence into adulthood. *J Adolesc Health* 2004;35:238–244.
20. Kitahata MM, Rodriguez BG, Haubrich R, *et al.*: Cohort profile: The Centers for AIDS Research (CFAR) Network of Integrated Clinical Systems (CNICS). *Int J Epidemiol* 2008;37:948–955.
21. Tien PC, Cole SR, Williams CM, *et al.*: Incidence of lipotrophy and lipohypertrophy in the Women's Interagency HIV study. *J Acquir Immune Defic Syndr* 2003; 34:461–466.
22. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C: The study of fat redistribution and metabolic change in HIV infection (FRAM): Methods, design, and sample characteristics. *Am J Epidemiol* 2006;163:860–869.
23. Crane HM, Grunfeld C, Harrington RD, Uldall KK, Ciechanowski PS, Kitahata MM: Lipotrophy among HIV-infected patients is associated with higher levels of depression than lipohypertrophy. *HIV Med* 2008;9:780–786.
24. Crane HM, Grunfeld C, Harrington RD, Kitahata MM: Lipotrophy and lipohypertrophy are independently associated with hypertension. *HIV Med* 2009;10:496–503.
25. Newcombe DA, Humeniuk RE, Ali R: Validation of the World Health Organization Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Report of results from the Australian site. *Drug Alcohol Rev* 2005; 24:217–226.
26. WHO ASSIST Working Group: The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): Development, reliability and feasibility. *Addiction* 2002;97: 1183–1194.
27. Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA: The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol Use Disorders Identification Test. *Arch Intern Med* 1998;158:1789–1795.
28. Bradley KA, Bush KR, Epler AJ, *et al.*: Two brief alcohol-screening tests From the Alcohol Use Disorders Identification Test (AUDIT): Validation in a female Veterans Affairs patient population. *Arch Intern Med* 2003;163:821–829.
29. Ainsworth BE, Jacobs DR, Jr., Leon AS: Validity and reliability of self-reported physical activity status: The Lipid Research Clinics questionnaire. *Med Sci Sports Exerc* 1993;25:92–98.
30. Crane HM, Lober W, Webster E, *et al.*: Routine collection of patient-reported outcomes in an HIV clinic setting: The first 100 patients. *Curr HIV Res* 2007;5:109–118.
31. Fredericksen RJ, Crane PK, Tufano J, *et al.*: Integrating a web-based patient assessment into primary care for HIV-infected adults. *J AIDS HIV Res* 2012;4:47–55.
32. Bradley KA, DeBenedetti AF, Volk RJ, Williams EC, Frank D, Kivlahan DR: AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res* 2007;31:1208–1217.
33. Sattler FR: Pathogenesis and treatment of lipodystrophy: What clinicians need to know. *Top HIV Med* 2008;16:127–133.
34. Diggle P, Heagerty P, Liang K, Zeger S: *Analysis of Longitudinal Data*. Oxford Press, Oxford, United Kingdom, 2002.
35. Cheng DM, Libman H, Bridden C, Saitz R, Samet JH: Alcohol consumption and lipodystrophy in HIV-infected adults with alcohol problems. *Alcohol* 2009;43:65–71.
36. Forrester JE, Gorbach SL: Fat distribution in relation to drug use, human immunodeficiency virus (HIV) status, and the use of antiretroviral therapies in Hispanic patients with HIV infection. *Clin Infect Dis* 2003;37 Suppl 2:S62–S68.
37. Chander G, Josephs J, Fleishman JA, *et al.*: Alcohol use among HIV-infected persons in care: Results of a multi-site survey. *HIV Med* 2008;9:196–202.
38. Galvan FH, Bing EG, Fleishman JA, *et al.*: The prevalence of alcohol consumption and heavy drinking among people with HIV in the United States: Results from the HIV Cost and Services Utilization Study. *J Stud Alcohol* 2002;63: 179–186.
39. Li J, Yang C, Davey-Rothwell M, Latkin C: Associations between body weight status and substance use among African American women in Baltimore, Maryland: The CHAT study. *Subst Use Misuse* 2016;51:669–681.
40. Barry D, Petry NM: Associations between body mass index and substance use disorders differ by gender: Results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Addict Behav* 2009;34:51–60.
41. Breslow RA, Smothers BA: Drinking patterns and body mass index in never smokers: National Health Interview Survey, 1997–2001. *Am J Epidemiol* 2005;161:368–376.
42. Hetherington MM, Cameron F, Wallis DJ, Pirie LM: Stimulation of appetite by alcohol. *Physiol Behav* 2001;74: 283–289.
43. Grunberg NE: The effects of nicotine and cigarette smoking on food consumption and taste preferences. *Addict Behav* 1982;7:317–331.
44. Foltin RW, Fischman MW, Byrne MF: Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. *Appetite* 1988;11:1–14.
45. Segatto AF, Freitas Junior IF, Santos VR, *et al.*: Lipodystrophy in HIV/AIDS patients with different levels of physical activity while on antiretroviral therapy. *Rev Soc Bras Med Trop* 2011;44:420–424.
46. Domingo P, Sambeat MA, Perez A, Ordonez J, Rodriguez J, Vazquez G: Fat distribution and metabolic abnormalities in HIV-infected patients on first combination antiretroviral therapy including stavudine or zidovudine: Role of physical activity as a protective factor. *Antivir Ther* 2003;8: 223–231.
47. Florindo AA, de Oliveira Latorre Mdo R, Jaime PC, Segurado AA: Leisure time physical activity prevents accumulation of central fat in HIV/AIDS subjects on highly active antiretroviral therapy. *Int J STD AIDS* 2007;18:692–696.
48. Jagers JR, Prasad VK, Dudgeon WD, *et al.*: Associations between physical activity and sedentary time on components of metabolic syndrome among adults with HIV. *AIDS Care* 2014;26:1387–1392.

49. Guaraldi G, Murri R, Orlando G, *et al.*: Morphologic alterations in HIV-infected people with lipodystrophy are associated with good adherence to HAART. *HIV Clin Trials* 2003;4:99–106.
50. Santos CP, Felipe YX, Braga PE, Ramos D, Lima RO, Segurado AC: Self-perception of body changes in persons living with HIV/AIDS: Prevalence and associated factors. *AIDS* 2005;19 Suppl 4:S14–S21.
51. Collins EJ, Burgoyne RW, Wagner CA, *et al.*: Lipodystrophy severity does not contribute to HAART non-adherence. *AIDS Behav* 2006;10:273–277.
52. Asensi V, Martin-Roces E, Collazos J, *et al.*: Association between physical and echographic fat thickness assessments and a lipodystrophy grading scale in lipodystrophic HIV patients: Practical implications. *AIDS Res Hum Retroviruses* 2006;22:830–836.
53. Burgoyne R, Collins E, Wagner C, *et al.*: The relationship between lipodystrophy-associated body changes and measures of quality of life and mental health for HIV-positive adults. *Qual Life Res* 2005;14:981–990.
54. van Belle G: Do not dichotomize unless absolutely necessary. In: *Statistical Rules of Thumb*. New York: John Wiley & Sons, 2002, pp. 99–100.
55. Lucas N, Windsor TD, Caldwell TM, Rodgers B: Psychological distress in non-drinkers: Associations with previous heavy drinking and current social relationships. *Alcohol Alcohol* 2010;45:95–102.
56. Liang W, Chikritzhs T: The association between alcohol exposure and self-reported health status: The effect of separating former and current drinkers. *PLoS One* 2013;8:e55881.

Address correspondence to:  
*Heidi M. Crane*  
*Department of Medicine*  
*University of Washington*  
*Harborview Medical Center*  
*325 9th Avenue, Box 359931*  
*Seattle, WA 98106*  
*E-mail: hcrane@uw.edu*